Lead Product(s) : MAX001
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : General Catalyst
Deal Size : $72.0 million
Deal Type : Series B Financing
Maxion Raises $72M Series A to Advance KnotBody® Pipeline And Platform
Details : Proceeds will be used to transform Maxion into a clinical-stage biotech company, taking the lead KnotBody programme MAX001. It is being evaluated for atopic dermatitis.
Product Name : MAX001
Product Type : Antibody
Upfront Cash : Undisclosed
March 17, 2025
Lead Product(s) : MAX001
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : General Catalyst
Deal Size : $72.0 million
Deal Type : Series B Financing
Lead Product(s) : Votucalis
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Votucalis is a broad-acting histamine inhibitor that was discovered through the same research program that yielded Akari’s lead drug, nomacopan, a complement and leukotriene inhibitor currently in Phase III clinical development.
Product Name : Votucalis
Product Type : Protein
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Votucalis
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-234
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Arcutis Biotherapeutics
Deal Size : $400.0 million
Deal Type : Acquisition
Details : DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.
Product Name : DS-234
Product Type : Protein
Upfront Cash : $16.0 million
August 09, 2022
Lead Product(s) : DS-234
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Arcutis Biotherapeutics
Deal Size : $400.0 million
Deal Type : Acquisition
Lead Product(s) : SDC-1801
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Product Name : SDC-1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : SDC-1801
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-234
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Arcutis Biotherapeutics
Deal Size : $30.0 million
Deal Type : Acquisition
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Details : DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.
Product Name : DS-234
Product Type : Protein
Upfront Cash : $16.0 million
July 09, 2022
Lead Product(s) : DS-234
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Arcutis Biotherapeutics
Deal Size : $30.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $505.5 million
Deal Type : Licensing Agreement
Details : Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases. The IL-17 family of cytokines are inducers of inflammation in variety of autoimmune diseases including psoriasis, psoriatic arthritis & a...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $7.3 million
December 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $505.5 million
Deal Type : Licensing Agreement